A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo Co., Ltd..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
127actual
Sites
29
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-22 | actual | When the study began enrolling |
| Primary completion | 2025-11-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-10 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Interventions
- Drug: Trastuzumab deruxtecan — also filed as DS-8201a, T-DXd
- Drug: Bevacizumab
Primary outcome
what the primary-completion date above is the date OFConfirmed Objective Response Rate (ORR)
measured An average of approximately 12 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed